Scarica l'app Stockscreener
0.4192
11.58%
0.0435
Dopo l'orario di chiusura:
.43
0.0108
+2.58%
Fibrobiologics Inc Borsa (FBLG) Ultime notizie
Top Executive Makes Bold Move Into FibroBiologics Stock - TipRanks
FibroBiologics completes site onboarding for diabetic ulcer trial - Investing.com
FibroBiologics completes site onboarding for diabetic ulcer trial By Investing.com - Investing.com Nigeria
FibroBiologics (FBLG) CSO Khoja buys $11k in stock - Investing.com
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers - The Manila Times
Fibroblast therapy moves toward Phase 1/2 trial for diabetic foot ulcers - Stock Titan
CEO Doubles Down on FibroBiologics With Bold Insider Stock Purchase - TipRanks
CFO’s Bold Insider Buy Sparks Fresh Buzz Around FibroBiologics Stock - TipRanks
Davis Jason, FibroBiologics CFO, buys $28973 in FBLG stock By Investing.com - Investing.com Australia
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Benzinga
Davis Jason, FibroBiologics CFO, buys $28973 in FBLG stock - Investing.com
FibroBiologics (FBLG) CFO purchases 70,000 shares in open-market trade - Stock Titan
Insider Makes Bold New Bet on FibroBiologics Stock - TipRanks
FBLG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
FibroBiologics Jumps 22% On New Osteoporosis Patent, Stock Up - Nasdaq
Garcia Ruben A, FibroBiologics general counsel, buys $13k in FBLG - Investing.com
FibroBiologics receives patent for osteoporosis cell therapy - Investing.com
Garcia Ruben A, FibroBiologics general counsel, buys $13k in FBLG By Investing.com - Investing.com South Africa
FibroBiologics, Inc. announces issuance of U.S. patent covering fibroblast cell therapy for the treatment of osteoporosis - marketscreener.com
Fibrobiologics, Inc. Announces Issuance Of U.S. Patent Covering Fibroblast Cell Therapy For The Treatment Of Osteoporosis - TradingView
New fibroblast cell therapy patent targets osteoporosis - Stock Titan
FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis - Sahm
FBLG: Ready to Transition to Clinical-Stage Company - Smartkarma
FBLG Technical Analysis & Stock Price Forecast - Intellectia AI
FibroBiologics to Present at the BIO Investment & Growth Summit - Bitget
H.C. Wainwright cuts FibroBiologics stock price target to $4 By Investing.com - Investing.com Canada
H.C. Wainwright cuts FibroBiologics stock price target to $4 - Investing.com Nigeria
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update - Bitget
FibroBiologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
FibroBiologics (FBLG) expands fibroblast-based cell therapy pipeline - Stock Titan
FibroBiologics gets Nasdaq extension to meet listing rules - Investing.com Australia
FibroBiologics gets Nasdaq extension to meet listing rules By Investing.com - Investing.com South Africa
FibroBiologics Shareholders Approve Reverse Split, Warrant Issuances - TipRanks
FibroBiologics shareholders approve reverse stock split and warrant share issuances - Investing.com Nigeria
FibroBiologics (NASDAQ: FBLG) investors approve reverse split and warrant shares - Stock Titan
FibroBiologics Granted Extension by Nasdaq to Regain Compliance - Bitget
FBLG PE Ratio & Valuation, Is FBLG Overvalued - Intellectia AI
Weekly Recap: Is FibroBiologics Inc stock overvalued or fairly pricedJuly 2025 Technicals & Growth Focused Entry Point Reports - baoquankhu1.vn
Analysis Recap: Is FibroBiologics Inc. benefiting from interest rate changesJuly 2025 Earnings & Real-Time Market Sentiment Reports - mfd.ru
How FibroBiologics Inc. stock reacts to inflationary pressuresJuly 2025 Patterns & Advanced Swing Trade Entry Alerts - mfd.ru
Should I add FibroBiologics Inc. stock to my portfolio2025 Earnings Impact & AI Based Buy/Sell Signal Reports - mfd.ru
FBLG Should I Buy - Intellectia AI
Aug Drivers: Can Xenetic Biosciences Inc be recession proofTrade Performance Summary & Long-Term Safe Investment Plans - baoquankhu1.vn
What’s the fair value of FibroBiologics Inc. stockJuly 2025 Recap & Daily Profit Focused Screening - mfd.ru
FibroBiologics CEO Pete O’Heeron to Speak at A4LI's H-SPAN Summit on Longevity Science - Quiver Quantitative
Longevity policy summit taps FibroBiologics CEO for main stage talk - Stock Titan
Is FibroBiologics Inc. benefiting from interest rate changesJuly 2025 Trends & Technical Pattern Based Signals - mfd.ru
FibroBiologics Faces Nasdaq Delisting Review After Noncompliance - TipRanks
FibroBiologics Received Notice of Delisting - TradingView
FibroBiologics Secures Canadian Patent for Innovative Cachexia Treatment Using Fibroblast Cells - Quiver Quantitative
FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia - ChartMill
FibroBiologics (NASDAQ:FBLG) Shares Down 1.6% – What’s Next? - Defense World
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):